Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.

Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, Suykens L, Oberste MS, Weldon WC, Costa-Clemens SA, Clemens R, Modlin J, Weiner AJ, Macadam AJ, Andino R, Kew OM, Konopka-Anstadt JL, Burns CC, Konz J, Wahid R, Gast C.

Lancet. 2019 Jul 13;394(10193):148-158. doi: 10.1016/S0140-6736(19)31279-6. Epub 2019 Jun 4.

2.

Breaking the Last Chains of Poliovirus Transmission: Progress and Challenges in Global Polio Eradication.

Kew O, Pallansch M.

Annu Rev Virol. 2018 Sep 29;5(1):427-451. doi: 10.1146/annurev-virology-101416-041749. Epub 2018 Jul 12. Review.

PMID:
30001183
3.

Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.

Shaw J, Jorba J, Zhao K, Iber J, Chen Q, Adu F, Adeniji A, Bukbuk D, Baba M, Henderson E, Dybdahl-Sissoko N, McDonald S, Weldon WC, Gumede N, Oberste MS, Kew OM, Burns CC.

J Virol. 2018 Apr 13;92(9). pii: e01949-17. doi: 10.1128/JVI.01949-17. Print 2018 May 1.

4.

Are Circulating Type 2 Vaccine-derived Polioviruses (VDPVs) Genetically Distinguishable from Immunodeficiency-associated VDPVs?

Zhao K, Jorba J, Shaw J, Iber J, Chen Q, Bullard K, Kew OM, Burns CC.

Comput Struct Biotechnol J. 2017 Oct 12;15:456-462. doi: 10.1016/j.csbj.2017.09.004. eCollection 2017.

5.

Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry.

Macklin G, Liao Y, Takane M, Dooling K, Gilmour S, Mach O, Kew OM, Sutter RW; iVDPV Working Group.

Front Immunol. 2017 Sep 25;8:1103. doi: 10.3389/fimmu.2017.01103. eCollection 2017.

6.

The Global Polio Laboratory Network as a Platform for the Viral Vaccine-Preventable and Emerging Diseases Laboratory Networks.

Diop OM, Kew OM, de Gourville EM, Pallansch MA.

J Infect Dis. 2017 Jul 1;216(suppl_1):S299-S307. doi: 10.1093/infdis/jix092.

7.

Pathogenic Events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic Poliomyelitis.

Shen L, Chen CY, Huang D, Wang R, Zhang M, Qian L, Zhu Y, Zhang AZ, Yang E, Qaqish A, Chumakov K, Kouiavskaia D, Vignuzzi M, Nathanson N, Macadam AJ, Andino R, Kew O, Xu J, Chen ZW.

J Virol. 2017 Jun 26;91(14). pii: e02310-16. doi: 10.1128/JVI.02310-16. Print 2017 Jul 15.

8.

Fifty Years of Global Immunization at CDC, 1966-2015.

Mast EE, Cochi SL, Kew OM, Cairns KL, Bloland PB, Martin R.

Public Health Rep. 2017 Jan/Feb;132(1):18-26. doi: 10.1177/0033354916681490. Epub 2016 Dec 19. No abstract available.

9.

Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame.

Pons-Salort M, Burns CC, Lyons H, Blake IM, Jafari H, Oberste MS, Kew OM, Grassly NC.

PLoS Pathog. 2016 Jul 6;12(7):e1005728. doi: 10.1371/journal.ppat.1005728. eCollection 2016 Jul.

10.

Molecular Properties of Poliovirus Isolates: Nucleotide Sequence Analysis, Typing by PCR and Real-Time RT-PCR.

Burns CC, Kilpatrick DR, Iber JC, Chen Q, Kew OM.

Methods Mol Biol. 2016;1387:177-212. doi: 10.1007/978-1-4939-3292-4_9.

PMID:
26983735
11.

Renaissance of an "old" vaccine.

Sutter RW, Kew OM.

Lancet Infect Dis. 2016 Mar;16(3):268-70. doi: 10.1016/S1473-3099(15)00526-5. Epub 2015 Dec 21. No abstract available.

PMID:
26719059
12.

An Insight into Recombination with Enterovirus Species C and Nucleotide G-480 Reversion from the Viewpoint of Neurovirulence of Vaccine-Derived Polioviruses.

Zhang Y, Yan D, Zhu S, Nishimura Y, Ye X, Wang D, Jorba J, Zhu H, An H, Shimizu H, Kew O, Xu W.

Sci Rep. 2015 Nov 25;5:17291. doi: 10.1038/srep17291.

13.

Comparing Israeli and Palestinian polio vaccination policies and the challenges of silent entry of wild poliovirus in 2013-14: a 'natural experiment'.

Flahault A, Orenstein W, Garon J, Kew O, Bickford J, Tulchinsky T.

Int J Public Health. 2015 Nov;60(7):765-6. doi: 10.1007/s00038-015-0700-0. No abstract available.

PMID:
26140857
14.

Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.

Diop OM, Burns CC, Sutter RW, Wassilak SG, Kew OM; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):640-6.

15.

Possible eradication of wild poliovirus type 3--worldwide, 2012.

Kew OM, Cochi SL, Jafari HS, Wassilak SG, Mast EE, Diop OM, Tangermann RH, Armstrong GL; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2014 Nov 14;63(45):1031-3.

16.

Polio-free certification and lessons learned--South-East Asia region, March 2014.

Bahl S, Kumar R, Menabde N, Thapa A, McFarland J, Swezy V, Tangermann RH, Jafari HS, Elsner L, Wassilak SG, Kew OM, Cochi SL.

MMWR Morb Mortal Wkly Rep. 2014 Oct 24;63(42):941-6.

17.

Development of an efficient entire-capsid-coding-region amplification method for direct detection of poliovirus from stool extracts.

Arita M, Kilpatrick DR, Nakamura T, Burns CC, Bukbuk D, Oderinde SB, Oberste MS, Kew OM, Pallansch MA, Shimizu H.

J Clin Microbiol. 2015 Jan;53(1):73-8. doi: 10.1128/JCM.02384-14. Epub 2014 Oct 22.

18.

Phylogeny of imported and reestablished wild polioviruses in theDemocratic Republic of the Congo from 2006 to 2011.

Gumede N, Jorba J, Deshpande J, Pallansch M, Yogolelo R, Muyembe-Tamfum JJ, Kew O, Venter M, Burns CC.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S361-7. doi: 10.1093/infdis/jiu375.

19.

Vaccine-derived polioviruses.

Burns CC, Diop OM, Sutter RW, Kew OM.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S283-93. doi: 10.1093/infdis/jiu295. Review.

PMID:
25316847
20.

A world without polio.

Cochi SL, Jafari HS, Armstrong GL, Sutter RW, Linkins RW, Pallansch MA, Kew O, Aylward RB.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S1-4. doi: 10.1093/infdis/jiu383. No abstract available.

PMID:
25316822
21.

Update on vaccine-derived polioviruses - worldwide, July 2012-December 2013.

Diop OM, Burns CC, Wassilak SG, Kew OM; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2014 Mar 21;63(11):242-8.

22.

The 2010 outbreak of poliomyelitis in Tajikistan: epidemiology and lessons learnt.

Yakovenko ML, Gmyl AP, Ivanova OE, Eremeeva TP, Ivanov AP, Prostova MA, Baykova OY, Isaeva OV, Lipskaya GY, Shakaryan AK, Kew OM, Deshpande JM, Agol VI.

Euro Surveill. 2014 Feb 20;19(7):20706.

23.

Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR.

Kilpatrick DR, Ching K, Iber J, Chen Q, Yang SJ, De L, Williams AJ, Mandelbaum M, Sun H, Oberste MS, Kew OM.

J Virol Methods. 2014 Mar;197:25-8. doi: 10.1016/j.jviromet.2013.11.017. Epub 2013 Dec 7.

PMID:
24321704
24.

Complete genome sequence of the last representative genotype of wild indigenous poliovirus type 1, which circulated in Brazil.

Tavares FN, da Costa EV, Kew OM, da Silva EE.

Genome Announc. 2013 Oct 31;1(6). pii: e00811-13. doi: 10.1128/genomeA.00811-13.

25.

Highly divergent type 2 and 3 vaccine-derived polioviruses isolated from sewage in Tallinn, Estonia.

Al-Hello H, Jorba J, Blomqvist S, Raud R, Kew O, Roivainen M.

J Virol. 2013 Dec;87(23):13076-80. doi: 10.1128/JVI.01174-13. Epub 2013 Sep 18.

26.

Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM.

Risk Anal. 2013 Apr;33(4):680-702. doi: 10.1111/risa.12022. Epub 2013 Mar 7.

PMID:
23470192
27.

Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria.

Burns CC, Shaw J, Jorba J, Bukbuk D, Adu F, Gumede N, Pate MA, Abanida EA, Gasasira A, Iber J, Chen Q, Vincent A, Chenoweth P, Henderson E, Wannemuehler K, Naeem A, Umami RN, Nishimura Y, Shimizu H, Baba M, Adeniji A, Williams AJ, Kilpatrick DR, Oberste MS, Wassilak SG, Tomori O, Pallansch MA, Kew O.

J Virol. 2013 May;87(9):4907-22. doi: 10.1128/JVI.02954-12. Epub 2013 Feb 13.

28.

Reaching the last one per cent: progress and challenges in global polio eradication.

Kew O.

Curr Opin Virol. 2012 Apr;2(2):188-98. doi: 10.1016/j.coviro.2012.02.006. Epub 2012 Mar 7. Review.

PMID:
22482715
29.

Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary.

Estívariz CF, Molnár Z, Venczel L, Kapusinszky B, Zingeser JA, Lipskaya GY, Kew OM, Berencsi G, Csohán A.

Am J Epidemiol. 2011 Aug 1;174(3):316-25. doi: 10.1093/aje/kwr070. Epub 2011 Jun 17.

PMID:
21685412
30.

Poliovirus vaccines: past, present, and future.

Nathanson N, Kew OM.

Arch Pediatr Adolesc Med. 2011 Jun;165(6):489-91. doi: 10.1001/archpediatrics.2011.77. No abstract available.

PMID:
21646582
31.

Poliovirus serotype-specific VP1 sequencing primers.

Kilpatrick DR, Iber JC, Chen Q, Ching K, Yang SJ, De L, Mandelbaum MD, Emery B, Campagnoli R, Burns CC, Kew O.

J Virol Methods. 2011 Jun;174(1-2):128-30. doi: 10.1016/j.jviromet.2011.03.020. Epub 2011 Apr 2.

PMID:
21440569
32.

Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population.

Wassilak S, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, Abanida EA, Adu F, Baba M, Gasasira A, Iber J, Mkanda P, Williams AJ, Shaw J, Pallansch M, Kew O.

J Infect Dis. 2011 Apr 1;203(7):898-909. doi: 10.1093/infdis/jiq140.

33.

Natural type 3/type 2 intertypic vaccine-related poliovirus recombinants with the first crossover sites within the VP1 capsid coding region.

Zhang Y, Zhu S, Yan D, Liu G, Bai R, Wang D, Chen L, Zhu H, An H, Kew O, Xu W.

PLoS One. 2010 Dec 21;5(12):e15300. doi: 10.1371/journal.pone.0015300.

34.

Type 2 vaccine-derived poliovirus from patients with acute flaccid paralysis in china: current immunization strategy effectively prevented its sustained transmission.

Zhang Y, Yan D, Zhu S, Wen N, Li L, Wang H, Liu J, Ye X, Ding Z, Wang D, Zhu H, Chen L, Hou X, An H, Liang X, Luo H, Kew O, Xu W.

J Infect Dis. 2010 Dec 15;202(12):1780-8. doi: 10.1086/657410. Epub 2010 Nov 4.

PMID:
21050127
35.

From emergence to eradication: the epidemiology of poliomyelitis deconstructed.

Nathanson N, Kew OM.

Am J Epidemiol. 2010 Dec 1;172(11):1213-29. doi: 10.1093/aje/kwq320. Epub 2010 Oct 26. Review.

36.

Emergence and localized circulation of a vaccine-derived poliovirus in an isolated mountain community in Guangxi, China.

Yan D, Li L, Zhu S, Zhang Y, An J, Wang D, Wen N, Jorba J, Liu W, Zhong G, Huang L, Kew O, Liang X, Xu W.

J Clin Microbiol. 2010 Sep;48(9):3274-80. doi: 10.1128/JCM.00712-10. Epub 2010 Jul 14.

37.

Limited duration of vaccine poliovirus and other enterovirus excretion among human immunodeficiency virus infected children in Kenya.

Khetsuriani N, Helfand R, Pallansch M, Kew O, Fowlkes A, Oberste MS, Tukei P, Muli J, Makokha E, Gary H.

BMC Infect Dis. 2009 Aug 23;9:136. doi: 10.1186/1471-2334-9-136.

38.

Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons.

Burns CC, Campagnoli R, Shaw J, Vincent A, Jorba J, Kew O.

J Virol. 2009 Oct;83(19):9957-69. doi: 10.1128/JVI.00508-09. Epub 2009 Jul 15.

39.

Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues.

Kilpatrick DR, Yang CF, Ching K, Vincent A, Iber J, Campagnoli R, Mandelbaum M, De L, Yang SJ, Nix A, Kew OM.

J Clin Microbiol. 2009 Jun;47(6):1939-41. doi: 10.1128/JCM.00702-09. Epub 2009 Apr 22.

40.

Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota.

Alexander JP, Ehresmann K, Seward J, Wax G, Harriman K, Fuller S, Cebelinski EA, Chen Q, Jorba J, Kew OM, Pallansch MA, Oberste MS, Schleiss M, Davis JP, Warshawsky B, Squires S, Hull HF; Vaccine-Derived Poliovirus Investigations Group.

J Infect Dis. 2009 Feb 1;199(3):391-7. doi: 10.1086/596052.

PMID:
19090774
41.

Estimating the extent of vaccine-derived poliovirus infection.

Wringe A, Fine PE, Sutter RW, Kew OM.

PLoS One. 2008;3(10):e3433. doi: 10.1371/journal.pone.0003433. Epub 2008 Oct 29.

42.

Polio today: are we on the verge of global eradication?

Cochi SL, Kew O.

JAMA. 2008 Aug 20;300(7):839-41. doi: 10.1001/jama.300.7.839. No abstract available.

PMID:
18714066
43.

Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia.

Shahmahmoodi S, Parvaneh N, Burns C, Asghar H, Mamishi S, Tabatabaie H, Chen Q, Teimourian S, Gooya MM, Esteghamati AR, Mousavi T, Yousefi M, Farrokhi K, Mashlool M, Kew O, Nategh R.

Virus Res. 2008 Oct;137(1):168-72. doi: 10.1016/j.virusres.2008.07.006. Epub 2008 Aug 15.

PMID:
18674576
44.

Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management.

Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM.

Risk Anal. 2008 Aug;28(4):855-76. doi: 10.1111/j.1539-6924.2008.01078.x. Epub 2008 Jul 4.

PMID:
18627544
45.

The risks, costs, and benefits of possible future global policies for managing polioviruses.

Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE Jr, Alexander J, Jafari H, Cochi SL.

Am J Public Health. 2008 Jul;98(7):1322-30. doi: 10.2105/AJPH.2007.122192. Epub 2008 May 29.

46.

Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range.

Jorba J, Campagnoli R, De L, Kew O.

J Virol. 2008 May;82(9):4429-40. doi: 10.1128/JVI.02354-07. Epub 2008 Feb 20.

47.

Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar.

Rakoto-Andrianarivelo M, Guillot S, Iber J, Balanant J, Blondel B, Riquet F, Martin J, Kew O, Randriamanalina B, Razafinimpiasa L, Rousset D, Delpeyroux F.

PLoS Pathog. 2007 Dec;3(12):e191.

48.

Molecular epidemiology of wild poliovirus type 1 circulation in West and Central Africa, from 1997 to 1999, using genotyping with a restriction fragment length polymorphism assay.

Gouandjika-Vasilache I, Burns CC, Gumede N, Guillot S, Ménard D, Dosseh A, Akoua-Koffi C, Pallansch MA, Kew OM, Delpeyroux F.

Arch Virol. 2008;153(3):409-16. Epub 2007 Dec 4.

PMID:
18060590
49.

Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency.

Parvaneh N, Shahmahmoudi S, Tabatabai H, Zahraei M, Mousavi T, Esteghamati AR, Gooya MM, Mamishi S, Nategh R, Kew OM.

J Clin Virol. 2007 Jun;39(2):145-8. Epub 2007 May 16.

PMID:
17509935
50.

Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child.

Adu F, Iber J, Bukbuk D, Gumede N, Yang SJ, Jorba J, Campagnoli R, Sule WF, Yang CF, Burns C, Pallansch M, Harry T, Kew O.

Virus Res. 2007 Jul;127(1):17-25. Epub 2007 Apr 20.

PMID:
17449127

Supplemental Content

Support Center